Clinical efficacy and pharmacodynamics of the insulin analogs lispro, aspart and glargin;Klinische wirkungen und pharmakodynamik der insulinanaloga lispro, aspart und glargin

Deutsche Medizinische Wochenschrift

Volumn 126, Issue 20, 2001, Pages 597-604

  Heinemann, L ^a   Heise, T ^a  

^a Profil Institut fur Stoffwechselforschung GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT;

DIABETES CONTROL; DRUG ABSORPTION; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; QUALITY OF LIFE; REVIEW;

BIOLOGICAL AVAILABILITY; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METABOLIC CLEARANCE RATE;

EID: 0035906874     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-14106     Document Type: Review

References (67)

1. Mealtime treatment with insulin analogue improves postprandial hyperglycemia and hypoglycemia in NIDDM patients
2. Improved mealtime treatment of diabetes mellitus using insulin analogue
3. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment
4. Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells
5. Towards more physiological insulin therapy in the 1990s. A comment
6. Safety of insulin glargine
7. Are presently available insulin analogues clinically beneficial?
8. The long acting human insulin analog HOE 901: Characteristics of insulin signalling in comparison to Asp(B10) and regular insulin
9. Insulin analogues and their potential in the management of diabetes mellitus
10. Insulin glargine
11. Intensified insulin therapy and the risk of severe hypoglycaemia
12. Effect of the insulin analogue insulin aspart on quality-of-life and treatment satisfaction in type 1 diabetic patients
13. Validation of a diabetic-specific quality-of-life scale for patients with type 1 diabetes
14. Monomeric insulins and their experimental and clinical implications
15. Monomeric insulins obtained by protein engineering and their medical implications
16. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type I diabetes
17. Post-prandial administration of the insulin analogue insulin aspart in patients with Type 1 diabetes mellitus
18. Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy
19. Why some cases of retinopathy worsen when diabetic control improves
20. Contribution of postprandial versus interprandial blood glucose to HbA1c in type I diabetes on physiologic intensive therapy with lispro insulin at mealtime
21. Improvement of blood glucose control in type 1 diabetic patients treated with lispro and multipe NPH injections
22. Strategies toward improved control during insulin lispro therapy in IDDM
23. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy
24. Pre-meal insulin analogue insulin lispro vs. Humulin R insulin treatment in young subjects with type 1 diabetes
25. Safety of insulin lispro: Pooled data from clinical trials
26. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: A randomized study
27. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency
28. Hypoglycemia and insulin analogues: Is there a reduction in the incidence?
29. Wirkungsprofile von normalinsulin NPH-insulin sowie einer 25/75-mischung hergestellt aus gentechnologischem bzw. semisynthetischem humaninsulin
30. Action profile of the rapid acting insulin analogue B28Asp
31. Prandial glycaemia after a carbohydrate-rich meal in type 1 diabetic patients using the rapid acting insulin analogue [Lys(B28), Pro(B29)]
32. Time-action profile of the insulin analogue B28Asp
33. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo
34. Variability of the metabolic effect of soluble insulin and the rapid acting insulin analogue insulin aspart
35. No evidence for accumulation of HOE901 after multiple injections in type 1 diabetic patients
36. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin
37. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy
38. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro
39. Rapid-acting insulin analogues: When randomized clinical trial results do not help
40. Improved glycemic control with insulin as part
41. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: A randomized controlled trial
42. Preclinical studies of rapid-acting insulin analogues
43. Effective and safe translation of intensified insulin therapy to general internal medicine departments
44. Subcutaneous insulin absorption explained by insulin's physicochemical properties. Evidence from absorption studies of soluble human insulin and insulin analogues in humans
45. Insulin analogues: Impact of cell model characteristics on results and conclusions regarding mitogenic properties
46. Health-related quality-of-life results from multinational clinical trials of insulin lispro
47. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use
48. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analogue lispro in variable combination with NPH insulin at mealtime
49. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long- acting human insulin analogue glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro
50. A review of the safety profile of insulin aspart
51. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps
52. Long-term complications of diabetes mellitus
53. Improved postprandial metabolic control after subcutaneous injection of a short acting insulin analog in IDDM of short duration with residual pancreatic-cell function
54. Efficacy safety of HOE901 versus NPH insulin in patients with type 1 diabetes
55. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes
56. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes
57. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes
58. Pharmacodynamic properties of insulin in patients with and without diabetic nephropathy
59. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial
60. Health-related quality of life and insulin lispro. A naturalistic approach
61. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens
62. A double-blind comparison of insulin lispro and regular insulin in patients on a multiple injection regimen
63. Comparison of pre-meal therapy with insulin lispo and regular insulin in patients with IDDM
64. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and ultralente human insulins using the euglycaemic clamp technique
65. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
66. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes
67. Insulin lispro in CSII: Results of a double-blind cross-over study